Loading
9MW2921 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
ASCO 2025 abstract 3029 reports 39 treated patients at the November 12, 2024 cutoff. Across doses, 12/38 efficacy-evaluable patients had partial responses. At 3.0 mg/kg, responses were 8/19 (42.1%); this is a dose subgroup, not the full treated population. All three patients at 4.5 mg/kg experienced dose-limiting toxicity and that dose was considered intolerable. The nonrandomized solid-tumor study does not establish TNBC-specific benefit.
TROP2-directed ADC carrying a camptothecin-based Mtoxin payload with site-specific conjugation. Connects to TROP2.
1.9MW2921's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"9MW2921" OR ABSTRACT:"9MW2921") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 9MW2921, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/